JP6168364B2 - リン酸化タウ凝集体に対する抗体 - Google Patents

リン酸化タウ凝集体に対する抗体 Download PDF

Info

Publication number
JP6168364B2
JP6168364B2 JP2014519581A JP2014519581A JP6168364B2 JP 6168364 B2 JP6168364 B2 JP 6168364B2 JP 2014519581 A JP2014519581 A JP 2014519581A JP 2014519581 A JP2014519581 A JP 2014519581A JP 6168364 B2 JP6168364 B2 JP 6168364B2
Authority
JP
Japan
Prior art keywords
antibody
tau
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014519581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523742A5 (cg-RX-API-DMAC7.html
JP2014523742A (ja
Inventor
ヨリス ウィンデリックス
ヨリス ウィンデリックス
ユージン ファンメヘレン
ユージン ファンメヘレン
ルーヴェン フレッド ファン
ルーヴェン フレッド ファン
Original Assignee
カソリック ウニヴェルシテイト ルーヴェン
カソリック ウニヴェルシテイト ルーヴェン
フジレビオ ユーロープ ナームローゼ フェンノートシャップ
フジレビオ ユーロープ ナームローゼ フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カソリック ウニヴェルシテイト ルーヴェン, カソリック ウニヴェルシテイト ルーヴェン, フジレビオ ユーロープ ナームローゼ フェンノートシャップ, フジレビオ ユーロープ ナームローゼ フェンノートシャップ filed Critical カソリック ウニヴェルシテイト ルーヴェン
Publication of JP2014523742A publication Critical patent/JP2014523742A/ja
Publication of JP2014523742A5 publication Critical patent/JP2014523742A5/ja
Application granted granted Critical
Publication of JP6168364B2 publication Critical patent/JP6168364B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
JP2014519581A 2011-07-14 2012-07-16 リン酸化タウ凝集体に対する抗体 Active JP6168364B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1112056.5A GB201112056D0 (en) 2011-07-14 2011-07-14 Antibodies
GB1112056.5 2011-07-14
PCT/EP2012/063924 WO2013007839A1 (en) 2011-07-14 2012-07-16 Antibodies to phosphorylated tau aggregates

Publications (3)

Publication Number Publication Date
JP2014523742A JP2014523742A (ja) 2014-09-18
JP2014523742A5 JP2014523742A5 (cg-RX-API-DMAC7.html) 2015-09-03
JP6168364B2 true JP6168364B2 (ja) 2017-07-26

Family

ID=44586547

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014519581A Active JP6168364B2 (ja) 2011-07-14 2012-07-16 リン酸化タウ凝集体に対する抗体

Country Status (6)

Country Link
US (1) US9447179B2 (cg-RX-API-DMAC7.html)
EP (1) EP2731969B1 (cg-RX-API-DMAC7.html)
JP (1) JP6168364B2 (cg-RX-API-DMAC7.html)
AU (1) AU2012282402B2 (cg-RX-API-DMAC7.html)
GB (1) GB201112056D0 (cg-RX-API-DMAC7.html)
WO (1) WO2013007839A1 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
CA2831480C (en) 2011-04-06 2020-09-29 Board Of Regents Of The University Of Texas System Lipid-based nanoparticles
ES2855165T3 (es) 2012-01-20 2021-09-23 Ananth Annapragada Métodos y composiciones para caracterizar objetivamente imágenes médicas
KR20200013072A (ko) 2012-07-03 2020-02-05 워싱턴 유니버시티 Tau에 대한 항체
AU2013302540B2 (en) * 2012-08-16 2018-02-15 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN105121465B (zh) * 2013-03-13 2020-09-08 普罗塞纳生物科技公司 Tau免疫疗法
RS60883B1 (sr) * 2013-06-10 2020-11-30 Ipierian Inc Metodi lečenja tauopatije
WO2015081085A2 (en) * 2013-11-27 2015-06-04 Ipierian, Inc. Methods of treating a tauopathy
SG11201605044RA (en) * 2013-12-20 2016-07-28 Hoffmann La Roche HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
EP2899208A1 (en) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
CN107106708B (zh) 2014-10-08 2021-06-18 德克萨斯州儿童医院 使用脂质体进行的淀粉样蛋白斑mri成像
WO2016055941A1 (en) * 2014-10-10 2016-04-14 National Research Council Of Canada Anti-tau antibody and uses thereof
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
CA3258972A1 (en) * 2015-06-05 2025-04-17 Ac Immune Sa TAU ANTIBODIES AND METHODS OF USING THEM
WO2016207245A1 (en) * 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
FI3452507T3 (fi) 2016-05-02 2022-12-15 Tau-immuunihoito
IL262726B2 (en) 2016-05-02 2024-07-01 Prothena Biosciences Ltd Antibodies recognizing tau
WO2017191561A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
WO2018017370A1 (en) * 2016-07-20 2018-01-25 Anahit Ghochikyan Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
US10988529B2 (en) 2016-08-09 2021-04-27 Eli Lilly And Company Combination therapy
KR101876423B1 (ko) 2016-10-10 2018-07-09 한국과학기술연구원 치매 모델 형질전환 마우스 및 이를 이용한 스크리닝 방법
FR3058143B1 (fr) * 2016-10-27 2021-03-12 Univ Grenoble Alpes Nanocorps anti-tau
WO2018106781A1 (en) 2016-12-07 2018-06-14 Genentech, Inc Anti-tau antibodies and methods of use
JP2020511937A (ja) 2016-12-07 2020-04-23 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
IL270375B2 (en) 2017-05-02 2024-12-01 Prothena Biosciences Ltd Antibodies recognizing tau
TWI853617B (zh) 2017-10-16 2024-08-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
EP3700556A2 (en) * 2017-10-25 2020-09-02 Janssen Pharmaceuticals, Inc. Compositions of phosphorylated tau peptides and uses thereof
BR112020018193A2 (pt) * 2018-03-05 2021-02-02 Janssen Pharmaceutica Nv ensaios para detectar neurodegeneração
US12234280B2 (en) 2018-03-05 2025-02-25 Janssen Pharmaceutica Nv Anti-PHF-tau antibodies and uses thereof
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
EP3885362A4 (en) * 2018-11-22 2022-08-17 Fujirebio Inc. Antibody conjugate
EP3894438A1 (en) * 2018-12-13 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
KR20210134943A (ko) 2019-03-03 2021-11-11 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
WO2023039107A2 (en) 2021-09-09 2023-03-16 Alzpath, Inc. Phospho-tau antibodies and methods of use
CN119708218B (zh) * 2024-11-19 2025-12-16 海南大学 分泌抗217位点苏氨酸磷酸化tau单克隆抗体的杂交瘤细胞株
CN119661705B (zh) * 2024-11-22 2025-06-24 上海伯杰医疗科技股份有限公司 一种抗p-Tau217蛋白单克隆抗体及其制备方法和应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
JP3909084B2 (ja) 1991-10-25 2007-04-25 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 微小管結合タンパク質タウに対するモノクローナル抗体
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
WO1995017429A1 (en) 1993-12-21 1995-06-29 Innogenetics N.V. Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
WO2004024090A2 (en) 2002-09-12 2004-03-25 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP1769002A1 (en) 2004-07-02 2007-04-04 Northwestern University Monolocal antibodies that target pathological assemblies of amyloid beta; (abeta)
EP1787998A4 (en) 2004-08-11 2008-08-27 Mitsubishi Chem Corp ANTIBODIES AND THEIR USE
JP5173426B2 (ja) 2004-10-25 2013-04-03 メルク・シャープ・エンド・ドーム・コーポレイション 抗ａｄｄｌ抗体およびこの使用
EP1951892A4 (en) 2005-11-22 2009-01-14 Univ Pennsylvania ANTIBODY TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISEASES
ZA200807228B (en) 2006-02-24 2009-11-25 Chiesi Farma Spa Anti-amyloid immunogenic compositions, methods and uses
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008070229A2 (en) * 2006-08-28 2008-06-12 Case Western Reserve University Detection of pathogenic aggregates of protein in a sample by homologous elisa
WO2008084402A2 (en) 2007-01-11 2008-07-17 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases
US20090155249A1 (en) 2007-06-12 2009-06-18 Ac Immune S.A. Humanized antibody igg1
US8932558B2 (en) * 2007-10-05 2015-01-13 Plaxgen Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
WO2009101942A1 (ja) * 2008-02-12 2009-08-20 Takeda Pharmaceutical Company Limited スクリーニング方法
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
JP5917394B2 (ja) * 2009-06-10 2016-05-11 ニューヨーク・ユニバーシティ 病理学的タウタンパク質の免疫学的標的化方法
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US9304138B2 (en) * 2010-10-07 2016-04-05 Katholieke Universiteit Leuven Pharmaceutical composition

Also Published As

Publication number Publication date
AU2012282402A1 (en) 2014-01-30
AU2012282402A2 (en) 2014-05-08
WO2013007839A1 (en) 2013-01-17
US20140161875A1 (en) 2014-06-12
EP2731969A1 (en) 2014-05-21
EP2731969B1 (en) 2018-10-17
GB201112056D0 (en) 2011-08-31
JP2014523742A (ja) 2014-09-18
AU2012282402B2 (en) 2017-03-09
US9447179B2 (en) 2016-09-20

Similar Documents

Publication Publication Date Title
JP6168364B2 (ja) リン酸化タウ凝集体に対する抗体
CN106574258B (zh) 抗-运甲状腺素蛋白人源化抗体
RU2442793C2 (ru) АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
CN101367875B (zh) N-11端截短的β-淀粉样蛋白的单克隆抗体、组合物、方法和用途
JP4729717B2 (ja) ＧＭ１ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするＤＮＡ
DK2732289T3 (en) ANTIBODIES, KIT AND IN VITRO METHOD FOR DETECTING BETA AMYLOID OLIGOMERS
CN106459956B (zh) 抗-运甲状腺素蛋白人抗体
JPWO2006137354A1 (ja) アミロイド線維形成に対する阻害活性を有する抗体
WO2005047860A2 (en) Antibodies to alpha-synuclein
US20250059265A1 (en) Alpha-synuclein single domain antibodies
JP2020511963A (ja) ヒトアルファ−シヌクレインに対する抗体
CN113508300A (zh) 用于人类阿尔茨海默病的新型生物标记物
WO2015004163A1 (en) Anti-tau monoclonal antibodies
KR20230003067A (ko) 미스폴딩된 tdp-43에 대한 단일쇄 항체 및 인트라바디 그리고 사용 방법
EP4293360A1 (en) Adult still's disease inspection method and inspection kit
JP7151985B2 (ja) 抗プロパノイル化アミロイドβタンパク質抗体
JP7221510B2 (ja) アミロイドβタンパク質におけるプロパノイル化修飾部位特異的測定方法
JPH0358797A (ja) 活性化小膠細胞に対するモノクローナル抗体、該モノクローナル抗体を分泌するハイブリドーマ、該モノクローナル抗体により識別される抗原及びこれらの製造方法
JP2006502409A (ja) バイオコンフォーマティック（ｂｉｏｃｏｎｆｏｒｍａｔｉｃ）分析のためのモノクローナル抗体
TWI892069B (zh) 用於偵測Tau蛋白或其片段的方法與套組
US20240358805A1 (en) Methods and materials to treat neurodegenerative disease
US11174310B2 (en) Disulfide-type HMGB1-specific antibody, method for measuring disulfide-type HMGB1 and kit for said measurement, and measurement method capable of quantitating all of HMGB1 molecules including reduced HMGB1, disulfide-type HMGB1 and thrombin-cleavable HMGB1 and kit for said measurement
US20230399387A1 (en) Antibodies for use in the detection and treatment of heart disease
KR20250122027A (ko) 고양이 혈청 아밀로이드 a 단백질에 대한 단일클론항체, 이를 생산하는 융합 세포주 및 이의 용도
JP2024506409A (ja) 抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160810

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170614

R150 Certificate of patent or registration of utility model

Ref document number: 6168364

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250